Reduction of MUC6 Expression Enhances Esophageal Epithelial Barrier Function and Suppresses Epithelial-Mesenchymal Transition in Reflux Esophagitis - Scorecard - MDSpire
Advertisement
Reduction of MUC6 Expression Enhances Esophageal Epithelial Barrier Function and Suppresses Epithelial-Mesenchymal Transition in Reflux Esophagitis
Clinical Scorecard: Reduction of MUC6 Expression Enhances Esophageal Epithelial Barrier Function and Suppresses Epithelial-Mesenchymal Transition in Reflux Esophagitis
At a Glance
Category
Detail
Condition
Reflux Esophagitis (RE)
Key Mechanisms
Involves dysregulation of MUC6, impacting epithelial barrier function and inflammatory response.
Target Population
Patients with reflux esophagitis, particularly those with symptoms unrelieved by standard treatment.
Care Setting
Endoscopic centers and hospitals specializing in gastroenterology.
Key Highlights
MUC6 expression is elevated in esophageal tissues of RE patients compared to non-RE patients.
Downregulation of MUC6 improves esophageal epithelial barrier function.
MUC6 may serve as a novel biomarker for early diagnosis and treatment of RE.
Guideline-Based Recommendations
Diagnosis
Confirm RE through gastroscopy and symptom assessment.
Management
Utilize proton-pump inhibitors (PPIs) and prokinetics; consider surgical interventions if necessary.
Monitoring & Follow-up
Regular endoscopic evaluations to assess mucosal injury and treatment efficacy.
Risks
Untreated RE can lead to esophageal ulcers and increased risk of esophageal cancer.
Patient & Prescribing Data
Patients diagnosed with reflux esophagitis, particularly those with persistent symptoms.
Combination therapy with PPIs and prokinetics is effective; novel biomarkers like MUC6 may enhance treatment strategies.
Clinical Best Practices
Monitor MUC6 levels as a potential biomarker for RE.
